Semaglutide vs. Tirzepatide: What the Latest Research Actually Says

For the first time, researchers have put semaglutide and tirzepatide head-to-head in a rigorously controlled clinical trial — and the results are reshaping how clinicians think about obesity pharmacotherapy. The 2025 SURMOUNT-5 trial published in the New England Journal of Medicine found that men and women with obesity who received tirzepatide lost an average of 20.2% of their body weight over 72 weeks, compared to 13.7% for those on semaglutide — a difference that was both statistically significant and clinically meaningful. Waist circumference shrank by 18.4 cm on tirzepatide versus 13.0 cm on semaglutide. These aren’t marginal differences. They represent a legitimate divergence in efficacy between two drugs that are often discussed as interchangeable.

But before drawing sweeping conclusions, it’s worth understanding why these two medications perform differently — and where the science gets more complicated.

Why Tirzepatide Outperforms Semaglutide on Weight Loss

Semaglutide is a selective GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a gut hormone that signals fullness, slows gastric emptying, and regulates blood sugar by stimulating insulin release. Tirzepatide does all of that — and adds a second mechanism. It also activates GIP (glucose-dependent insulinotropic polypeptide) receptors, making it a dual agonist. That dual action appears to create a more powerful metabolic signal, producing greater appetite suppression and more substantial fat loss.

This wasn’t theoretical. The SURPASS-2 trial, published in the New England Journal of Medicine in 2021, randomized nearly 1,900 patients with type 2 diabetes to tirzepatide at three doses or semaglutide 1 mg. Tirzepatide was superior at every dose for reducing HbA1c, and body weight reductions were significantly greater across the board — with the 15 mg tirzepatide arm showing a 5.5 kg advantage over semaglutide. A 2024 systematic review and network meta-analysis in Diabetologia that pooled 28 randomized controlled trials and over 23,000 participants confirmed this pattern: tirzepatide 15 mg was the most efficacious treatment across the board for reducing HbA1c and body weight in adults with type 2 diabetes. The dual-agonist mechanism isn’t just a marketing distinction — it’s producing measurably different clinical outcomes.

For men pursuing fat loss — whether through medication, nutrition strategies, or both — these numbers matter. A 20% reduction in body weight for someone at 240 lbs means losing roughly 48 lbs. A 13.7% reduction means losing about 33 lbs. Both are clinically significant. But the 15-pound gap between them is the difference between hitting a target and falling meaningfully short of it.

Where Semaglutide Holds Its Ground

The SURMOUNT-5 weight loss data makes tirzepatide look like the obvious winner, but the cardiovascular picture is more nuanced — and for men with existing heart disease, it may be the more important variable.

A large real-world study published in 2026 in Diabetes, Obesity & Metabolism — called the STEER analysis — examined over 10,000 patients per group with overweight or obesity and established atherosclerotic cardiovascular disease (ASCVD) but no diabetes. Semaglutide was associated with a statistically significant 29% lower risk of major adverse cardiovascular events (MACE-3: heart attack, stroke, all-cause mortality) compared to tirzepatide. In a per-protocol analysis that accounted for treatment adherence, that advantage grew to 57% lower risk. These findings don’t suggest tirzepatide is harmful — both drugs dramatically outperform doing nothing — but they raise a legitimate question about which agent is preferable when cardiovascular risk reduction is the primary goal.

That question becomes even more interesting when looking at heart failure specifically. A 2025 JAMA study using national US health care claims data examined patients with heart failure with preserved ejection fraction (HFpEF) — a condition closely linked to obesity and metabolic dysfunction that’s notoriously difficult to treat. Both semaglutide and tirzepatide reduced the composite risk of hospitalization for heart failure or all-cause mortality by more than 40% compared to a placebo proxy. But when the two drugs were compared directly, tirzepatide showed no meaningful advantage over semaglutide. In the context of cardiometabolic heart failure, they appear to perform comparably despite tirzepatide’s superior weight loss profile.

This tells us something important: weight loss magnitude and cardiovascular protection don’t always move in lockstep. The mechanisms driving heart failure risk reduction — anti-inflammatory effects, reduced cardiac load, improved endothelial function — may be shared between the two drug classes at sufficient doses, even when weight outcomes diverge. For men who are primarily focused on reducing cardiovascular risk rather than hitting a specific weight target, semaglutide may still be a highly rational choice, particularly given its longer safety track record and the now-extensive SELECT trial data supporting its cardiac benefits.

On the safety side, both drugs share a common profile. Gastrointestinal side effects — nausea, diarrhea, vomiting — are the most frequent complaints with both, and they tend to be mild to moderate, occurring mainly during dose escalation. The SURMOUNT-5 trial confirmed this pattern even at the highest doses of each agent. Neither drug is risk-free, but both are well-characterized at this point across tens of thousands of clinical trial participants and millions of real-world users.

What This Means For You

If you’re deciding between these medications in consultation with your physician, the research now offers clearer guidance than it did even two years ago. For men whose primary goal is maximum fat loss and metabolic improvement without existing cardiovascular disease, tirzepatide has a statistically significant and clinically meaningful advantage. For men with established heart disease or a strong cardiovascular risk profile, semaglutide’s real-world cardiac data — including the landmark SELECT trial and now the STEER analysis — gives it a compelling argument. For men with heart failure, the two appear roughly equivalent on the outcomes that matter most.

It’s also worth remembering that pharmacotherapy works best when layered onto a solid foundation of resistance training, adequate protein intake, and consistent sleep. These medications suppress appetite effectively, but the men who preserve the most muscle mass and see the best long-term body composition outcomes are the ones who use that appetite suppression as an opportunity to eat higher-quality food and continue training — not as a substitute for either. The science on these drugs is evolving rapidly. What isn’t changing is that the fundamentals still apply.